











# The leading Belarusian manufacturer and exporter of medicines










## MISSION:

Helping to protect, strengthen and restore people's health.







## **ADVANTAGES:**



59 years of successful work



Supplies to more than 15 countries of the world



Availability and efficiency



Multistage quality control system



More than 300 products in brand portfolio



Well-organized system of logistics and storage of manufactured products





### **ENTERPRISE SCHEME**



#### 2nd production area (64 Chapaeva str.)

- 1 Production site for sterile liquid dosage forms in ampoules (workshop №1)
- 2 Production site for antibiotics in form of powders for injections in vials (workshop №5)
  3 PUE «Frebor»
- 4 Production site for non-sterile solid dosage forms (workshop №4)
- **4A** Production site for non-sterile solid dosage forms (prospective)

#### 1st production area (24 Stroiteley str.)

- **5** Production site for non-sterile liquid and soft dosage forms (workshop №2)
- 6 Production site for non-sterile solid dosage forms (workshop №3)

#### Investment project (78 Chapaeva str.)


- 7 Administration building
- 8 Finished products warehouse
- **9** Medicinal products manufacturing site (prospective)





### **VOLUME OF MEDICINES PRODUCTION**











#### **ASSORTMENT PORTFOLIO**



## More than 300

names of medicines

**12** pharmacotherapeutic groups

7 - 8 new medicines mastered every year









#### MAIN DOSAGE FORMS

solutions for injections in vials (antibiotics)

tablets (including modified release tablets)


capsules liquid phytochemical drugs (tinctures, medical drops)

soft dosage forms (ointments, gels)

# 300 technologies for medicines production







# THE ENTERPRISE SPECIALIZES IN THE PRODUCTION OF medicinal products for the treatment of:










## PRODUCT PORTFOLIO














## DOMESTIC TRADING PARTNERS



## Structure of domestic market sales in 2023



- State-owned enterprises (RUE «Pharmacia»)
- **■** Commercial enterprises







#### SALES GEOGRAPHY



More than 50% of produced medicines are exported annually

BORIMED supplies its products to overseas markets through distribution network consisting of 120 distributors. Medicines are exported to 15 countries worldwide: to CIS countries, Asian and African countries






#### **EXPORT SALES GEOGRAPHY**



Share in the total exports volume, %



- Russia (52,2%)
- Kazakhstan (13,2%)
- Uzbekistan (12,5%)
- Azerbaijan (6,9%)
- Turkmenistan (3,4%)
- Kyrgyzstan (2,5%)
- Moldova (1,5%)
- Armenia (2,5%)
- Georgia (3,2%)
- Tajikistan (1,3%)
- Iraq, Macedonia, Mongolia, Serbia (0,5%)







# INVESTMENT PROJECTS UNDER IMPLEMENTATION



Name of investment project	Implementation terms	Costs, mln USD
Creation of a new production site for solid dosage forms	2021-2029	59.3
Reconstruction of an industrial building on an area of 8.3 hectares for a warehouse for finished products	2021-2024	11.7







## Investment project «Creation of a new production site for solid dosage forms»



**Goal:** increase in economic efficiency of the company's activity by creating new production facilities.

Implementation terms: 2021-2029

Capital costs: 59.3 mln USD







# Investment project «Creation of a new production site for solid dosage forms»

#### Indicators of effectiveness of the project:


Project capacity – 1336 mln tablets per year

Output to project capacity – 1st quarter of 2029

Annual revenue of the new production site after the output to project capacity – 24 mln USD

Export orientation of the project (excess of exports over imports) – **55,6%** 

Planned quantity of created workplaces by the project – 174 (including 40 new modernized positions)




■ Loan
■ Own funds








## Investment project «Reconstruction of an industrial building on the area of 8.3 hectares for a warehouse for finished products»





**Goal:** reconstruction of the industrial building on the area of 8,3 hectares for a warehouse for finished products with multi-level storage in accordance with the GMP standard requirements.

Implementation terms: 2021-2024

Capital costs: 11.7 mln USD

Multi-level storage warehouse for finished products with the capacity of 6260 pallet positions that meets the GMP standard requirements will reduce logistics costs, transportation costs, rental and maintenance costs, and will lead to the increase in flexibility in customer service.

The project is implemented according to the plan








#### Pharmaceutical Quality System (PQS)





BORIMED has an efficiently functioning pharmaceutical quality system that provides control at all production stages.







#### Pharmaceutical Quality System (PQS)



Ensuring and control of product quality at all levels of production are carried out by the specialized quality division consisting of:

- quality assurance department;
- quality control department: control group, analytical and microbiological laboratories;
- pharmacovigilance bureau.

The quality division is aimed at the assurance of the effective functioning of the pharmaceutical quality system, which includes:

- quality management system;
- Good Manufacturing Practice (GMP);
- quality control;
- quality-related risks management;
- regular and recurrent products quality control.







#### Pharmaceutical Quality System (PQS)



 All BORIMED production facilities are certified for compliance of the medicines manufacturing process with the EAEU and national Good Manufacturing Practice requirements.









#### Награды













- BORIMED The leader in the sphere of import substitution
- Folic acid 0,4 mg «Product of the year 2023»
- The Republic of Belarus Government Prize for Quality in 2019
- From 2014 till 2018 BORIMED was the winner of the Consumer Recognition Prize of "People's Choice Brand of Belarus".
- BORIMED diploma winner of «Best Exporter of 2022»









